These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22704124)

  • 1. Inability to access buprenorphine treatment as a risk factor for using diverted buprenorphine.
    Lofwall MR; Havens JR
    Drug Alcohol Depend; 2012 Dec; 126(3):379-83. PubMed ID: 22704124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of diverted buprenorphine use among adults entering corrections-based drug treatment in Kentucky.
    Smith KE; Tillson MD; Staton M; Winston EM
    Drug Alcohol Depend; 2020 Mar; 208():107837. PubMed ID: 31951906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The complex relation between access to opioid agonist therapy and diversion of opioid medications: a case example of large-scale misuse of buprenorphine in the Czech Republic.
    Mravčík V; Janíková B; Drbohlavová B; Popov P; Pirona A
    Harm Reduct J; 2018 Dec; 15(1):60. PubMed ID: 30514306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scope of, Motivations for, and Outcomes Associated with Buprenorphine Diversion in the United States: A Scoping Review.
    Rubel SK; Eisenstat M; Wolff J; Calevski M; Mital S
    Subst Use Misuse; 2023; 58(5):685-697. PubMed ID: 36803159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Buprenorphine in the United States: Motives for abuse, misuse, and diversion.
    Chilcoat HD; Amick HR; Sherwood MR; Dunn KE
    J Subst Abuse Treat; 2019 Sep; 104():148-157. PubMed ID: 31370979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diversion and abuse of buprenorphine: findings from national surveys of treatment patients and physicians.
    Johanson CE; Arfken CL; di Menza S; Schuster CR
    Drug Alcohol Depend; 2012 Jan; 120(1-3):190-5. PubMed ID: 21862241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the Abuse and Diversion of the Buprenorphine Transdermal Delivery System.
    Wiegand TJ; Le Lait MC; Bartelson BB; Dart RC; Green JL
    J Pain; 2016 Jun; 17(6):745-52. PubMed ID: 26996928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. When Prescribing Isn't Enough - Pharmacy-Level Barriers to Buprenorphine Access.
    Cooper HLF; Cloud DH; Young AM; Freeman PR
    N Engl J Med; 2020 Aug; 383(8):703-705. PubMed ID: 32813945
    [No Abstract]   [Full Text] [Related]  

  • 9. Assessing Motivations for Nonprescribed Buprenorphine Use Among Rural Appalachian Substance Users.
    McDonald MJ; DeVeaugh-Geiss AM; Chilcoat HD; Havens JR
    J Addict Med; 2023 Jan-Feb 01; 17(1):95-100. PubMed ID: 36044288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users.
    Bazazi AR; Yokell M; Fu JJ; Rich JD; Zaller ND
    J Addict Med; 2011 Sep; 5(3):175-80. PubMed ID: 21844833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. County-level access to opioid use disorder medications in medicare Part D (2010-2015).
    Abraham AJ; Adams GB; Bradford AC; Bradford WD
    Health Serv Res; 2019 Apr; 54(2):390-398. PubMed ID: 30665272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Buprenorphine Supply, Access, and Quality: Where We Have Come and the Path Forward.
    Breen CT; Fiellin DA
    J Law Med Ethics; 2018 Jun; 46(2):272-278. PubMed ID: 30147002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the use of diverted buprenorphine.
    Cicero TJ; Ellis MS; Chilcoat HD
    Drug Alcohol Depend; 2018 Dec; 193():117-123. PubMed ID: 30359928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human immunodeficiency virus testing practices among buprenorphine-prescribing physicians.
    Edelman EJ; Dinh AT; Moore BA; Schottenfeld RS; Fiellin DA; Sullivan LE
    J Addict Med; 2012 Jun; 6(2):159-65. PubMed ID: 22367499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diversion of methadone and buprenorphine by patients in opioid substitution treatment in Sweden: prevalence estimates and risk factors.
    Johnson B; Richert T
    Int J Drug Policy; 2015 Feb; 26(2):183-90. PubMed ID: 25465344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees.
    Wen H; Hockenberry JM; Pollack HA
    JAMA Netw Open; 2018 Sep; 1(5):e182943. PubMed ID: 30646185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diversion of methadone and buprenorphine from opioid substitution treatment: the importance of patients' attitudes and norms.
    Johnson B; Richert T
    J Subst Abuse Treat; 2015 Jul; 54():50-5. PubMed ID: 25744650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Office-Based Opioid Treatment with Buprenorphine (OBOT-B): Statewide Implementation of the Massachusetts Collaborative Care Model in Community Health Centers.
    LaBelle CT; Han SC; Bergeron A; Samet JH
    J Subst Abuse Treat; 2016 Jan; 60():6-13. PubMed ID: 26233698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term self-treatment with methadone or buprenorphine as a response to barriers to opioid substitution treatment: the case of Sweden.
    Richert T; Johnson B
    Harm Reduct J; 2015 Feb; 12():1. PubMed ID: 25889208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term retention in Office Based Opioid Treatment with buprenorphine.
    Weinstein ZM; Kim HW; Cheng DM; Quinn E; Hui D; Labelle CT; Drainoni ML; Bachman SS; Samet JH
    J Subst Abuse Treat; 2017 Mar; 74():65-70. PubMed ID: 28132702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.